drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous CAR T cells)
drug_description
Autologous T cells genetically engineered to express an anti-CD20 chimeric antigen receptor, redirecting T cells to recognize CD20 on malignant B cells and induce TCR-independent activation, cytokine release, cytotoxic killing, and in vivo expansion.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express an anti-CD20 chimeric antigen receptor that recognizes CD20 on malignant B cells and triggers TCR-independent activation through CAR signaling, leading to cytokine release, proliferation, and targeted cytotoxic killing of CD20-positive cells.
drug_name
LY007 CD20 CAR-T cell infusion
nct_id_drug_ref
NCT06049381